Chemical Sunscreens and Bloodstream Absorption: The FDA Clinical Trial Explained
When consumers apply sun protection, they often assume the active filters remain entirely on the skin surface. However, a major randomized clinical trial published in JAMA in 2020 evaluated whether active chemical sunscreen ingredients enter systemic circulation under maximal-use conditions. Understanding this research helps clarify how the FDA regulates sunscreen ingredients, while underscoring why individuals researching skin health should rely on evidence and board-certified dermatologists rather than unapproved online substances like unregulated melanotan peptides.
Background: How the FDA Defined the Absorption Threshold
Under federal regulatory guidance, active ingredients that show systemic absorption exceeding a threshold of 0.5 warrant additional safety evaluation, specifically nonclinical toxicology testing. A prior pilot study showed that some sunscreen ingredients entered systemic circulation, prompting the need for a larger investigation. In the 2020 study, federal researchers set out to measure the systemic absorption and pharmacokinetics of 6 common active ingredients: avobenzone, oxybenzone, octocrylene, homosalate, octisalate, and octinoxate. The core objective was to determine whether systemic exposure surpassed the 0.5 mark and how quickly that occurred.
Trial Design: Forty-Eight Volunteers in a Controlled Pharmacology Unit
The randomized clinical trial took place between January and February 2019 at a clinical pharmacology unit in West Bend, Wisconsin. The trial enrolled 48 healthy participants, with 44 volunteers (92%) completing the protocol. The study cohort included 24 women (50%) and 24 men, with an overall mean age of 38.7 years (standard deviation, 13.2). In terms of reported race and ethnicity, the trial included 23 white participants (48%), 23 African American participants (48%), 1 Asian participant (2%), and 1 participant of unknown race or ethnicity (2%).
Investigators randomized participants into 4 groups to test different commercial product formulations:
- Lotion (12 participants)
- Aerosol spray (12 participants)
- Nonaerosol spray (12 participants)
- Pump spray (12 participants)
The Application and Blood Collection Timeline
The trial evaluated single-application and maximal-use exposure over an intensive schedule registered under ClinicalTrials.gov identifier NCT03582215. Sunscreen product was applied to 75% of each participant's body surface area. On day 1, volunteers received an initial application at 0 hours. On day 2 through day 4, the product was applied 4 times per day at 2-hour intervals. Across the entire evaluation window, researchers collected 34 blood samples over 21 days from each participant.
The primary outcome was the maximum plasma concentration of avobenzone over days 1 through 21. Secondary outcomes measured the maximum plasma concentrations of oxybenzone, octocrylene, homosalate, octisalate, and octinoxate across that same 21-day window.
Findings: Blood Levels Exceeded the Regulatory Cutoff on Day One
Geometric mean maximum plasma concentrations for all 6 active ingredients exceeded the 0.5 threshold. Notably, this threshold was surpassed on day 1 after a single application for every ingredient evaluated. The recorded values varied across the active filters and formulation types:
- Avobenzone: Maximum plasma concentrations were 7.1 (coefficient of variation, 73.9%) for lotion, 3.5 (coefficient of variation, 70.9%) for aerosol spray, 3.5 (coefficient of variation, 73.0%) for nonaerosol spray, and 3.3 (coefficient of variation, 47.8%) for pump spray.
- Oxybenzone: Plasma concentrations reached 258.1 (coefficient of variation, 53.0%) for lotion and 180.1 (coefficient of variation, 57.3%) for aerosol spray.
- Octocrylene: Concentrations were 7.8 (coefficient of variation, 87.1%) for lotion, 6.6 (coefficient of variation, 78.1%) for aerosol spray, and 6.6 (coefficient of variation, 103.9%) for nonaerosol spray.
- Homosalate: Concentrations reached 23.1 (coefficient of variation, 68.0%) for aerosol spray, 17.9 (coefficient of variation, 61.7%) for nonaerosol spray, and 13.9 (coefficient of variation, 70.2%) for pump spray.
- Octisalate: Values reached 5.1 (coefficient of variation, 81.6%) for aerosol spray, 5.8 (coefficient of variation, 77.4%) for nonaerosol spray, and 4.6 (coefficient of variation, 97.6%) for pump spray.
- Octinoxate: Values were 7.9 (coefficient of variation, 86.5%) for nonaerosol spray and 5.2 (coefficient of variation, 68.2%) for pump spray.
Adverse Events, Study Limits, and Clinical Context
Regarding tolerability, the most common adverse event was rash, which developed in 14 participants during the study. Beyond skin reactions, the researchers noted in their clinical pharmacology trial report that systemic absorption above 0.5 does not imply toxicity or harm. Instead, exceeding 0.5 means the active ingredient surpasses the administrative threshold for potentially waiving additional nonclinical safety testing. The authors explicitly concluded that these findings do not indicate that individuals should refrain from sunscreen use.
Readers should also consider the structural limits of this single trial. The protocol tested maximal-use conditions in an indoor clinic setting, without exposure to sunlight, heat, humidity, or exercise. It monitored healthy adult volunteers over 21 days and was not designed to evaluate long-term health outcomes. When considering sunscreen formulations and broad-spectrum protection, consumers should weigh clinical data in consultation with a dermatologist. This rigorous scientific scrutiny highlights the sharp difference between tested topical sunscreens and illegal, unregulated peptides like melanotan I or melanotan II sold online, which lack safety oversight entirely.
Sources
Published October 31, 2026. Sources are linked in the text. See our Medical Disclaimer.